Roche’s Vabysmo maintains vision gains with extended intervals in late-stage RVO patient trial
In the trial, patients treated with Vabysmo extended their treatment intervals up to every four months while maintaining…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Oct 23
In the trial, patients treated with Vabysmo extended their treatment intervals up to every four months while maintaining…
05 Oct 23
As per the results from the Phase 1/2 study, the vaccine was found effective against all four A…
05 Oct 23
The second IDE Study will be conducted for the safety and efficacy for the treatment of knee OA…
29 Sep 23
.The proceeds of the financing will support the advancement of Deka’s pipeline and drug product manufacturing as they…
27 Sep 23
In the study, the results showed a statistically significant reduction in TG levels with the olezarsen 80 mg…
26 Sep 23
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of…
25 Sep 23
Compared to chemotherapy, the combination met its dual primary endpoints of overall survival and progression-free survival showing a…
14 Sep 23
In the trial, the vaccine generated a strong immune response against all four A and B strains of…
12 Sep 23
The CHRYSALIS-2 study cohort evaluated the safety and tolerability of the combination of Rybrevant with Lazertinib plus platinum-based…
08 Sep 23
The two-part, multicenter, open-label, first-in-human phase 1/2 trial will assess the safety and efficacy of DS-3939 in patients…